Pericytes augment glioblastoma cell resistance to temozolomide through CCL5-CCR5 paracrine signaling

Glioblastoma (GBM) is a prevalent and highly lethal form of glioma, with rapid tumor progression and frequent recurrence. Excessive outgrowth of pericytes in GBM governs the ecology of the perivascular niche, but their function in mediating chemoresistance has not been fully explored. Herein, we uncovered that pericytes potentiate DNA damage repair (DDR) in GBM cells residing in the perivascular niche, which induces temozolomide (TMZ) chemoresistance. We found that increased pericyte proportion correlates with accelerated tumor recurrence and worse prognosis. Genetic depletion of pericytes in GBM xenografts enhances TMZ-induced cytotoxicity and prolongs survival of tumor-bearing mice. Mechanistically, C-C motif chemokine ligand 5 (CCL5) secreted by pericytes activates C-C motif chemokine receptor 5 (CCR5) on GBM cells to enable DNA-dependent protein kinase catalytic subunit (DNA-PKcs)-mediated DDR upon TMZ treatment. Disrupting CCL5-CCR5 paracrine signaling through the brain-penetrable CCR5 antagonist maraviroc (MVC) potently inhibits pericyte-promoted DDR and effectively improves the chemotherapeutic efficacy of TMZ. GBM patient-derived xenografts with high CCL5 expression benefit from combined treatment with TMZ and MVC. Our study reveals the role of pericytes as an extrinsic stimulator potentiating DDR signaling in GBM cells and suggests that targeting CCL5-CCR5 signaling could be an effective therapeutic strategy to improve chemotherapeutic efficacy against GBM.Subject terms: Cancer microenvironment, CNS cancer, Cancer therapy     

胭脂鱼胰岛素样生长因子-Ⅰ(IGF-Ⅰ)cDNA的分子克隆、序列分析及组织表达

参考多种生物的胰岛素样生长因子-Ⅰ(IGF-Ⅰ)基因序列,设计并合成引物。用胭脂鱼(Myxocyprinus asiaticus)肝总RNA逆转录得到cDNA并扩增获得特异性片段,回收纯化后亚克隆到pMD-18T载体上。测序后经序列比对分析表明,所得到的序列是胭脂鱼胰岛素样生长因子-Ⅰ(IGF-Ⅰ)cDNA片段,共489bp,包括该基因完整的开放阅读框(ORF)486bp,编码162个氨基酸。氨基酸序列与其他鲤形目鱼类具有较高的同源性,对胭脂鱼IGF-Ⅰ在一些组织中的表达研究发现,IGF-Ⅰ在肝中表达最多,其次是胰、性腺,在脑、垂体、鳃、心、脾中也有不同程度的表达,而在肠、肾、肌肉中的表达不十分明显。     

胭脂鱼胰蛋白酶cDNA 克隆以及不同蛋白含量日粮和饥饿对mRNA 表达和酶活力的影响

为检测不同蛋白含量的日粮和饥饿对胭脂鱼(Myxocyprinus asiaticus)幼鱼胰蛋白酶活性和mRNA表达的影响, 首先用RACE 和PCR 的方法从胭脂鱼幼鱼的肝胰脏组织中克隆得到胰蛋白酶cDNA 全长, 然后用半定量RT-PCR 和酶活性检测方法分别检测了经不同蛋白含量日粮(酪蛋白含量分别为35%、45% 和 55%)投喂和饥饿处理后的胭脂鱼幼鱼的胰蛋白酶mRNA 表达水平和胰蛋白酶活力的变化。结果显示, 胭脂鱼胰蛋白酶cDNA 全长为912 bp。投喂蛋白质含量适中(45%酪蛋白)日粮组的试验鱼胰蛋白酶活性和mRNA 水平高于投喂高蛋白水平日粮组(55%酪蛋白)和低蛋白水平日粮组(35% 酪蛋白); 饥饿明显降低mRNA水平和胰蛋白酶活性; 胰蛋白酶活性的变化滞后于mRNA 水平的变化。胰蛋白酶活力的变化与mRNA 水平的变化之间未呈现直接相关性。因此, 胭脂鱼胰蛋白酶合成可能是一个由多种因素共同调控的复杂过程。       

蛾类昆虫性信息素受体及其作用机理

蛾类昆虫性信息素受体首先从烟芽夜蛾Heliothis virescens和家蚕Bombyx mori中鉴定出来, 到目前为止已经克隆得到了19种蛾类昆虫的几十种性信息素受体基因, 并且这些基因在系统发育树中聚成一个亚群。性信息素受体从蛾类蛹期开始表达, 主要表达在雄性触角的毛形感器中, 少部分受体在雌性触角、 雄性触角其他感器以及身体其他部位中也有表达。大部分蛾类性信息素受体的配体并不是单一的, 而是能够对多种性信息素组分有反应, 部分性信息素受体还能够识别性信息素以外的其他物质, 还有一部分性信息素受体的识别配体目前尚不清楚。另外发现在雌性蛾类触角中也存在一些嗅觉受体能够识别雄性分泌的性信息素。在蛾类性信息素受体与性信息素识别的过程中, 性信息素结合蛋白不仅能够特异性地运送配体到嗅觉神经元树状突上, 还能够提高性信息素与性信息素受体之间的结合效率。另外, OrCo类受体与性信息素受体共表达在嗅觉神经元中, 在蛾类性信息素受体与配体的识别过程中扮演了重要角色。但是蛾类信息素对神经元刺激的终止并非由性信息素受体控制, 而是由细胞中的气味降解酶等其他因子调控。蛾类性信息素受体研究中还有很多疑问需要解答, 其过程可能比我们想象的更为复杂。     

Essential Role of Hrs in Endocytic Recycling of Full-length TrkB Receptor but Not Its Isoform TrkB.T1

Brain-derived neurotrophic factor (BDNF) signaling through its receptor, TrkB, modulates survival, differentiation, and synaptic activity of neurons. Both full-length TrkB (TrkB-FL) and its isoform T1 (TrkB.T1) receptors are expressed in neurons; however, whether they follow the same endocytic pathway after BDNF treatment is not known. In this study we report that TrkB-FL and TrkB.T1 receptors traverse divergent endocytic pathways after binding to BDNF. We provide evidence that in neurons TrkB.T1 receptors predominantly recycle back to the cell surface by a “default” mechanism. However, endocytosed TrkB-FL receptors recycle to a lesser extent in a hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs)-dependent manner which relies on its tyrosine kinase activity. The distinct role of Hrs in promoting recycling of internalized TrkB-FL receptors is independent of its ubiquitin-interacting motif. Moreover, Hrs-sensitive TrkB-FL recycling plays a role in BDNF-induced prolonged mitogen-activated protein kinase (MAPK) activation. These observations provide evidence for differential postendocytic sorting of TrkB-FL and TrkB.T1 receptors to alternate intracellular pathways.Brain-derived neurotrophic factor (BDNF)³ has been shown to play critical roles in vertebrate nervous system development and function (1–3). The actions of BDNF are dictated by two classes of cell surface receptors, the TrkB receptor and the p75 neurotrophin receptor. BDNF binding to TrkB receptors activates several signaling cascades, including phosphatidylinositol 3-kinase, phospholipase C, and Ras/mitogen-activated protein kinase (MAPK) pathways, that mediate growth and survival responses to BDNF (1, 4, 5). It has been established that upon binding neurotrophins, Trk receptors are rapidly endocytosed in a clathrin-dependent manner (6, 7). Postendocytic sorting of Trk receptors to diverse pathways after ligand binding has a significant impact on the physiological responses to neurotrophins because they also determine the strength and duration of intracellular signaling cascades initiated by activated Trk receptors (8). Three alternate endocytic pathways that Trk receptors can follow are trafficking to lysosomes for degradation, recycling back to the plasma membrane, or being retrogradely transported (9–13). The degradative pathway to lysosomes is characterized by down-regulation of the total number of receptors at the cell surface and a decreased response to ligand. Conversely, recycling of receptors back to the plasma membrane can lead to functional resensitization and prolongation of cell surface-specific signaling events. A recent study has shown that recycled and re-secreted BDNF plays an important role in mediating the maintenance of long term potentiation in hippocampal slices, which suggests a potential role of TrkB recycling in long term potentiation regulation (14).Different TrkB isoforms, including the full-length TrkB (TrkB-FL) and three truncated isoforms named TrkB.T1, TrkB.T2, and TrkB.T-Shc, exist in the mammalian central nervous system because of alternative splicing (15–17). Truncated TrkB.T1 receptor lacks the kinase domain but contains short isoform-specific cytoplasmic domain in its place (15, 16). Many neuronal populations, including hippocampal and cortical neurons, express both full-length and truncated TrkB receptors (18, 19). TrkB.T1 is expressed at low levels in the prenatal rodent brain, but its expression increases postnatally, ultimately exceeding the level of full-length TrkB in adulthood (19–22). The physiological function of the TrkB.T1 receptor remains unclear, but it may serve as dominant-negative regulator of full-length TrkB receptors (23–25), may sequester ligand and limit diffusion (26, 27), may regulate cell morphology and dendritic growth (28, 29), and may even autonomously activate signaling cascades in a neurotrophin-dependent manner (30). TrkB-FL and TrkB.T1 are localized to both somatodendritic and axonal compartments in neurons (31); however, little is known about TrkB.T1 endocytic trafficking fate upon BDNF treatment.In this study we conducted an analysis of the postendocytic fates (degradation and recycling) of TrkB-FL and TrkB.T1 receptors in PC12 cells and neurons. We have determined that, unlike TrkB-FL, TrkB.T1 receptors recycle more efficiently in a default pathway to plasma surface after internalization, which is independent of hepatocyte growth factor-regulated tyrosine kinase substrate (Hrs). Conversely, Hrs could bind with TrkB-FL in a kinase activity-dependent manner and regulate TrkB-FL receptors postendocytic recycling. Hrs was identified as a tyrosine-phosphorylated protein in cells stimulated with growth factors and cytokines (32). Hrs is expressed in the cytoplasm of all cells and is predominantly localized to endosomes (33). Hrs has also been proposed to play a role in regulating cell surface receptor postendocytic trafficking (34). These observations provide evidence for differential postendocytic sorting to alternate intracellular pathways between TrkB-FL and TrkB.T1 receptors after internalization.     

A glycolysis-based ten-gene signature correlates with the clinical outcome,molecular subtype and IDH1 mutation in glioblastoma

Reprogrammed metabolism is a hallmark of cancer. Glioblastoma (GBM) tumor cells predominantly utilize aerobic glycolysis for the biogenesis of energy and intermediate nutrients. However, in GBM, the clinical significance of glycolysis and its underlying relations with the molecular features such as IDH1 mutation and subtype have not been elucidated yet. Herein, based on glioma datasets including TCGA (The Cancer Genome Atlas), REMBRANDT (Repository for Molecular Brain Neoplasia Data) and GSE16011, we established a glycolytic gene expression signature score (GGESS) by incorporating ten glycolytic genes. Then we performed survival analyses and investigated the correlations between GGESS and IDH1 mutation as well as the molecular subtypes in GBMs. The results showed that GGESS independently predicted unfavorable prognosis and poor response to chemotherapy of GBM patients. Notably, GGESS was high in GBMs of mesenchymal subtype but low in IDH1-mutant GBMs. Furthermore, we found that the promoter regions of tumor-promoting glycolytic genes were hypermethylated in IDH1-mutant GBMs. Finally, we found that high GGESS also predicted poor prognosis and poor response to chemotherapy when investigating IDH1-wildtype GBM patients only. Collectively, glycolysis represented by GGESS predicts unfavorable clinical outcome of GBM patients and is closely associated with mesenchymal subtype and IDH1 mutation in GBMs.     

米曲霉M-4降解己烯雌酚的条件优化

【目的】以米曲霉(Aspergillus oryzae)M-4对己烯雌酚(Diethylstilbestrol,DES)的降解率为响应值,对其降解条件进行优化。【方法】采用Plackett-Burman法对培养基组分和降解条件筛选显著性影响因素,并通过Box-Bohnken设计试验优化降解条件。【结果】最优培养基配方为:蛋白胨1.3%,CaCl_2 0.045%,葡萄糖0.5%,K_2HPO_4 0.15%,KH_2PO_4 0.05%,NaCl 0.05%,Tween 80 0.2%,DES质量浓度44 mg/L;最优培养条件为:初始p H 7.5,种龄72 h,转速140 r/min,培养温度28°C,培养时间72 h。【结论】在最优条件下菌株M-4对DES降解率为83.89%,比优化前(60.98%)提高1.38倍,差异极显著(P0.01)。     

From nutraceutical to clinical trial: frontiers in Ganoderma development

Ganoderma spp. are medical mushrooms with various pharmacological compounds which are regarded as a nutraceutical for improving health and treating diseases. This review summarizes current progress in the studies of Gamoderma ranging from bioactive metabolites, bioactivities, production techniques to clinical trials. Traditionally, polysaccharides and ganoderic acids have been reported as the major bioactive metabolites of Ganoderma possessing anti-tumor and immunomodulation functions. Moreover, recent studies indicate that Gandoerma also exerts other bioactivities such as skin lighting, gut microbiota regulation, and anti-virus effects. However, since these medical fungi are rare in natural environment, and that the cost of cultivation of fruiting bodies is high, industrial submerged fermentation of Ganoderma mycelia promotes the development of Ganoderma by dint of an increase of biomass and bioactive metabolites used for further application. In addition, various strategies for production of different metabolites are well developed, such as gene regulation, bi-stage pH, and oxygen control. To date, Ganoderma not only has become one of the most popular nutraceuticals worldwide but also has been applied to clinical trials for advanced diseases such as breast and non-small-cell lung cancer.